【US Stock Movement】Kodiak Sciences plummeted on October 13: sharp correction after surge, overvalued, and uncertain financing approval

Kodiak Sciences October 13 Sharp Decline Analysis

Keywords: Surge Retracement, Overvaluation, Financing Approval Uncertainty

1. On September 28, 2026, the company announced that the DAYBREAK Phase III trial met its primary endpoint, resulting in a significant single-day stock price surge. As of October 8, related data show a notable increase in the past month, with valuations above some models and industry levels. Quick profit-taking after rapid revaluation could intensify the retracement.

2. As of September 30, 2026, the company remains in the pre-commercialization stage. Reports mention quarterly cash burn exceeding 60 million USD and cash around 126 million USD, with potential financing possibly leading to equity dilution. Zenkuda still needs to submit an application and obtain regulatory approval, leaving the commercialization process uncertain.

(Disclaimer: This content is generated by AI technology based on publicly available information and is for reference only. It does not constitute investment advice.)